YDES
YD Bio Ltd
Healthcare · ·
$3.01
Data: 2026-06-03
✓ ETHICAL PASS
NONE MOAT
LIMITED
Data Confidence: 0.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$265M
Total market value of the company
N/A
Rev Growth
+95.6%
Year-over-year revenue change
Profit Margin
-276.6%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
NONE
Consensus view from ? analysts covering this stock
About YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
Country: Taiwan Industry: Biotechnology
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PENDING
Debt must be below 33% of total assets
Cash Ratio
0.0% PENDING
Interest-bearing cash below 33% of assets
Receivables
0.0% PENDING
Receivables below 49% of assets
Revenue Purity
0.0% PENDING
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-84.6%
Historical annualised return based on price data
Days in State
168
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
52W High
$25.00
88% below the year high
52W Low
$2.88
5% above the year low
Avg Volume
17,904
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
30.4%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-444.6%
Profit from core operations before interest and tax
Revenue (TTM)
$510,360
Total revenue over the last 12 months
Net Income
$-1,411,559
Loss-making — spending exceeds revenue after all costs
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03